Switching from Ozempic to Wegovy
The short answer
For switching from Ozempic to Wegovy, the Wegovy label gives no dose conversion. Its switching section covers only Wegovy injection and Wegovy tablets. The label's starting dose for the injection is 0.25 mg once weekly, and it says using Wegovy with other semaglutide-containing products isn't recommended. Self-pay Wegovy pens cost $349 a month at most doses.
Key takeaways
- Both contain semaglutide, but no label converts an Ozempic dose into a Wegovy dose. Your prescriber decides where you start.
- The Wegovy label says not to use it with other semaglutide products, so Wegovy replaces Ozempic.
- Paying cash through NovoCare? Wegovy pens from 1 mg to 2.4 mg cost $349 a month.
- A plan that covers Ozempic for type 2 diabetes may still exclude Wegovy for weight reduction. Call your plan first.
- Wegovy pens are single-use, four to a carton. Ask your pharmacist to show you how the new pen works.
What the labels say about switching from Ozempic to Wegovy
The Wegovy label gives one starting dose for everyone: 0.25 mg once weekly. It gives no dose conversion from Ozempic.
The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.
The Wegovy label says using Wegovy tablets or Wegovy injection together with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
FDA label: Revised: 6/2026 (DailyMed version 19)
| How you pay | Per fill | |
|---|---|---|
| Ozempic 2 mg | NovoCare self-pay | $499 |
| Wegovy 0.25 mg | Measured | $248 |
Try other combinations in the switching planner. Switching is a prescriber decision.
Ozempic and Wegovy are both semaglutide injections from Novo Nordisk, taken once a week. Each has its own label and approved uses. Ozempic is for adults with type 2 diabetes. Wegovy is for long-term weight reduction, for lowering cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, and for MASH. A pharmacy can’t swap one for the other. To move, you need a new prescription.
What do the labels say about this switch?
Nothing specific. The Wegovy label has a switching section, but it only covers moving between Wegovy injection and Wegovy tablets. It doesn’t mention Ozempic. The Ozempic injection label gives no switching steps either. Its only related text is about moving from Ozempic injection to semaglutide tablets.
What the Wegovy label does say is that using it with other semaglutide-containing products isn’t recommended. Read plainly, that means you don’t stay on Ozempic while you start Wegovy.
What dose does the Wegovy label start at?
The label’s recommended starting dose for the injection is 0.25 mg once weekly. Its dose table then moves through 0.5 mg, 1 mg and 1.7 mg in 4-week steps, up to the usual maintenance dose (the dose you stay on) of 2.4 mg from week 17. The label says this slow climb is there to lower the risk of stomach and bowel side effects. For adults who need more weight reduction after at least 4 weeks on 2.4 mg, it allows an increase to a top dose of 7.2 mg once weekly.
The label gives that schedule for everyone starting Wegovy. It doesn’t say how earlier Ozempic treatment changes it. That question goes to your prescriber. We don’t convert doses between the two products.
The pen is different
Ozempic comes as a multi-dose pen that takes a new needle for each injection. Wegovy single-dose pens come four to a carton, and you use each pen only once. Your weekly routine carries over: the Wegovy label also says to inject on the same day each week, at any time of day, with or without meals. Ask your pharmacist to walk you through the new pen.
What does the switch cost?
If you pay cash, the two are priced alike. NovoCare’s self-pay price is $349 a month for Wegovy pens from 1 mg to 2.4 mg. Ozempic is $349 at 0.5 mg or 1 mg and $499 at 2 mg. If you’re new to the Wegovy offer, you pay $199 a month for up to two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Wegovy pill is a separate form, priced from $149 a month.
If your commercial insurance covers the drug, each product has its own savings offer that brings a fill down to as little as $25. The Wegovy cost page has the full table.
How does coverage change?
This is the part that surprises people. An insurer that pays for Ozempic for type 2 diabetes is covering a diabetes drug. Wegovy prescribed for weight reduction falls under the plan’s weight-management rules, and some plans exclude those drugs outright.
Medicare shows the split clearly. CMS lists type 2 diabetes as a use that can be covered under Part D, while the Part D law excludes drugs used for weight loss. Eligible people can get Wegovy for weight management through the Medicare GLP-1 Bridge at $50 a month. But people with type 2 diabetes aren’t eligible for the Bridge, and neither is anyone who got a GLP-1 through their Part D plan in 2026. The Medicare and Wegovy page explains each route.
Questions for your prescriber
- Which approved Wegovy use is the prescription for? That drives coverage.
- What dose will you be prescribed, and when should your first Wegovy injection fall after your last Ozempic dose?
- If you have type 2 diabetes, how does the change affect your other blood sugar medicines? The Wegovy label notes a higher risk of low blood sugar when it’s used with insulin or a sulfonylurea (a type of diabetes pill).
- Will the office file the prior authorization (the plan’s approval before it pays) before your current pen runs out?
Compare other pairs in the switching planner, or read the full Wegovy guide.
Frequently asked questions
Can I go from Ozempic 1 mg straight to Wegovy 1 mg?
The labels don't say yes or no. Both products have a 1 mg strength, but the Wegovy label gives no steps for people coming from Ozempic. It states a starting dose of 0.25 mg once weekly. Whether your time on Ozempic changes where you begin on Wegovy is your prescriber's decision. A label doesn't settle it.
Can I take Ozempic and Wegovy together?
The Wegovy label says no. Its limitations of use say that taking Wegovy with other semaglutide-containing products, or with any other GLP-1 receptor agonist, isn't recommended. Ozempic contains semaglutide, so a switch means one replaces the other. Your prescriber sets the date the change happens.
Is Wegovy cheaper than Ozempic without insurance?
At most doses, the self-pay prices are the same. Wegovy pens are $349 a month from 0.25 mg to 2.4 mg and $399 for the 7.2 mg pen. Ozempic is $349 at 0.5 mg and 1 mg and $499 at 2 mg. Both prices are NovoCare self-pay offers that don't use insurance.
Why would insurance cover Ozempic but not Wegovy?
Because plans cover a drug for a specific use. Ozempic is approved for adults with type 2 diabetes. Wegovy is approved for weight reduction, cardiovascular risk reduction and MASH. A plan can cover diabetes medicines and exclude weight-loss medicines, and the Medicare Part D law excludes drugs used for weight loss. The diagnosis your prescriber puts on the prior authorization decides which rules apply.
Sources (14)
- 1.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 2.FDA label (DailyMed): Wegovy prescribing information, Instructions for Use (single-dose pen)
“Your WEGOVY pen is for 1 time use only. The WEGOVY pen is for subcutaneous (under the skin) use only.”
- 3.FDA label (DailyMed): Wegovy prescribing information, section 16
“WEGOVY injection is a clear, colorless solution available in cartons containing 4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch) as follows:”
- 4.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
- 5.FDA label (DailyMed): Wegovy prescribing information, section 7.1
“The risk of hypoglycemia is increased when WEGOVY is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas). The addition of WEGOVY in patients treated with insulin has not been evaluated.”
- 6.FDA label (DailyMed): Ozempic prescribing information, section 16
“Always remove and safely discard the needle after each injection and store the OZEMPIC pen without an injection needle attached. Always use a new needle for each injection.”
- 7.FDA label (DailyMed): Ozempic prescribing information, section 16
“Each OZEMPIC multi-dose pen is for use by a single patient. An OZEMPIC pen must never be shared between patients, even if the needle is changed”
- 8.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 9.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 10.
- 11.
- 12.
- 13.
- 14.
